<DOC>
	<DOCNO>NCT01067950</DOCNO>
	<brief_summary>Current medical therapy able prevent progression establish macroproteinuira ( i.e . diabetic nephropathy ) end-stage renal failure type 1 ( insulin dependent ) diabetic patient . In set , proteinuria major risk factor mortality . Pancreas transplantation , contrary , revert diabetic nephropathy thereby prevent end-stage chronic renal failure , theoretically low risk death compare current medical therapies.The main objective study assess superiority isolate pancreas transplantation versus intensive exogenous insulin therapy type 1 diabetic patient overt diabetic nephropathy mildly reduce renal function . The primary endpoint composite efficacy/failure end-point include : patient mortality renal function impairment 5 year patient badly control diabetes nephropathy resist up-to-date nephroprotective therapies.Main secondary objective safety efficacy regimen , include proteinuria renal histology evaluation , metabolic control quality life , acute chronic extrarenal complication diabetes , pancreas survival risk related transplant procedure ( anaesthesia , surgery immunosuppression side-effects ) intensive insulin therapy management .</brief_summary>
	<brief_title>Pancreas Allotransplantation Diabetic Nephropathy Mild Chronic REnal fAilure Stage Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Patients enrol study meet follow criterion : Type 1 diabetic patient age 25 55 year time randomisation . Fasting plasma Cpeptide 0.5 ng/ml . Badly control diabetes despite optimized insulin regimen consist continuous subcutaneous insulin infusion ( via insulin pump ) multiple daily injection insulin Persistent 24hour proteinuria 300 mg/day ( mean 3 sample ) despite adapt antiproteinuric therapy least 6 month . Cystatin C and/or Cr51EDTA and/or DMSATc scintigraphy measure glomerular filtration rate 60 90 ml/min . No contraindication pancreas transplant surgery Woman childbearing potential must negative serum pregnancy test enrolment must agree maintain effective birth control first year study . Capable understanding purpose risk study , fully inform give write informed consent ( sign Informed Consent obtain ) . Affiliated national insurance . Patients exclude participate follow criterion apply : Patient type 2 diabetes and/or fast plasma Cpeptide 0.5 ng/ml . Pregnant woman breastfeed mother . Woman childbearing potential unwilling maintain effective birth control first year study Second transplant recipient recipient functional graft organ . Proteinuria 300 mg/day ( mean 3 sample ) . Albuminemia le 30 g/l . Cystatin C and/or Cr51EDTA and/or DMSATc scintigraphy measure glomerular filtration rate lower 60 ml/min high 90 ml/min . Presence document nondiabetic systemic disease potentially affect kidney . Known allergy , hypersensibility intolerance know insulin , recommend immunosuppressive agent study ( Thymoglobulin , antilymphocyte serum Fresenius , tacrolimus , cyclosporin , mycophenolate mofetil , mycophenolic acid , corticosteroid etc ) , mocrolides antibiotic , compound excipient product . Currently participate another clinical trial and/or take investigational drug within four week prior enrolment . Diagnosis newonset malignancy 5 year enrolment . Significant , uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer . Patient affect active B hepatitis ( HBsAg positive , HBeAg positive HBVDNA positive ) active C hepatitis ( HCVAb positive ; HCVRNA positive ) . Patient HIV positive . Any form substance abuse , psychiatric disorder condition , opinion investigator , may complicate communication investigator . Obesity ( body mass index 30 kg/m2 ) . Severe iliac vessel calcification impede surgery . Advanced coronary artery disease Left ventricular function le 30 % . Plasma blood leukocytes less 2,000 /mm3 high 15,000/mm3 Plasma blood platelet le 60,000 /mm3 high 500,000/mm3 Psychological disorder influence drug compliance . Unable , unwilling unlikely comply fully protocol visit schedule .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>isolate pancreas transplant</keyword>
	<keyword>intensive insulin therapy</keyword>
</DOC>